CVS Health reports Q1 2026 results on May 6 as a stock that has quietly re-rated higher — and with the short sellers who drove much of the bearish narrative now stepping back.
Short interest has fallen sharply over the past month. At roughly 1.3% of the free float, it has dropped nearly 20% in the past 30 days and shed another 14% over the past week. Borrow costs have followed — running at just 0.37% annually, down roughly 28% over the same period. Availability remains wide and loose, well above any level that would signal squeeze pressure. The ORTEX short score of 29.5 sits in a comfortable range. This is not a stock where the bears are making a bold stand heading into earnings.
Options positioning tells a similar story. The put/call ratio is running at 0.76, modestly above its 20-day average of 0.72 — barely three-quarters of a standard deviation above the mean. That is far from defensive territory; the 52-week high is 0.98. The stock itself has added 14% over the past month to close at $82.09, and gained 5% just in the past week alone, with a modest pullback of 1.4% on Friday. The sector context is supportive: close peers UNH, , and all gained 4–9% on the week, and the entire managed-care complex looks to have stabilised after earlier turbulence.
The analyst setup is broadly constructive, though the consensus sits at hold with only three hold ratings captured — a thin sample. Baird raised its target to $94 in mid-April, maintaining Outperform. Bernstein upgraded CVS to Outperform in March, also targeting $94. Piper Sandler trimmed slightly to $99 while keeping Overweight. The analyst mean target implies roughly 18% upside from current levels. Bulls point to script share growth above 28%, strong Health Services revenue momentum, and the ongoing Oak Street Health integration. Bears flag the lack of material EPS growth — FY26 EPS is seen roughly 5% below prior estimates — and headwinds in the insurance segment, including declining claims volume and rising medical cost ratios. The EPS surprise factor rank of 93rd percentile suggests the company has consistently beaten reduced expectations; whether that pattern holds is the operative question.
T. Rowe Price added nearly 3 million shares in the most recent filing period, one of the more notable institutional moves among the top holders. The broader ownership picture is stable, with BlackRock, Vanguard, and Capital Research all marginally adding. Insider activity on April 1 saw the CEO and several senior executives sell small amounts at $72.49 — well below the current price, reflecting routine vesting-related disposals rather than directional conviction. Historical earnings reactions have been muted: the last two prints produced one-day moves of +1.6% and -0.7%, with five-day drifts staying in a similarly narrow range.
The May 6 print, then, is less about short covering or volatility than about whether management can demonstrate that the insurance segment losses are bottoming — and whether the pharmacy and health services engine can sustain the revenue trajectory that justified a 14% monthly re-rating.
See the live data behind this article on ORTEX.
Open CVS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
